key: cord-0870851-x9v75phv authors: Ji, Fang; Liu, Wen; Hao, Da-ang; Cheng, Juan; Tong, Xue-cheng; Hao, Jun-gui; Wang, Li-ping; Li, Chun-yang; Dai, Ming-jia; Yan, Xue-bing title: Use of convalescent plasma therapy in Eight mild COVID-19 patients date: 2020-11-13 journal: New Microbes New Infect DOI: 10.1016/j.nmni.2020.100814 sha: 1c1ad4703a871beeaecf2049d3b1be25b88a4723 doc_id: 870851 cord_uid: x9v75phv The coronavirus disease 2019 (COVID-19) is still global epidemic. Several studies of severe COVID-19 patients regard convalescent plasma (CP) transfusion as an effective therapy. However, there are no significant improvements in the randomized clinical trial of CP treatment. Until now, the data of mild COVID-19 patients transfused CP were lack. This study recruited 8 mild COVID-19 patients received at least one dose of CP transfusion. After CP therapy, all patients improved the clinical symptoms. The level of lymphocyte counts tended to increase, meanwhile LDH, CK and AST tended to decrease. However, CRP of 3 patients increased transiently. The median time that SARS-CoV-2 nucleic acid of the patients turned to negative was 2.5d after CP transfusion. The study shows the potential benefits of CP. Meanwhile, CP probably enhances the inflammatory response to SARS-CoV-2 temporarily in the patients with insufficient antiviral immunity. However, the effects of CP are not permanent. As of July 23th, the coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected almost 15 million patients with more than 600 000 deaths all over the world. SARS-CoV-2 belongs to the coronavirus family and spreads more quickly than SARS-CoV from person to person [1] . COVID-19 is primarily an acute viral pneumonia and can cause respiratory failure [2] , though some of the COVID-19 patients were asymptomatic. Currently, there is no approved antiviral agent that can effectively target this novel virus. Since vaccines and antiviral medicines are unavailable, the treatment is mainly experimental or empirical. Convalescent plasma (CP) refers to plasma that is collected from individuals with resolution of infection and development of antibodies. CP was employed successfully as post-exposure prophylaxis and/or treatment for SARS-CoV, Middle East Respiratory Syndrome [MERS] and Ebola [3, 4] . This study screened 40 recovered COVID-19 patients, among which 39 displayed neutralizing antibody with titers larger than or equal to 160 (97.5%) [5] . Although current studies of severe COVID-19 patients demonstrated the potential efficacy of CP therapy [6, 7] . there is a lack of sufficient data for common COVID-19 patients treated with transfusion of convalescent plasma. Thus, we performed this pilot study with cases from multiple centers (four hospitals) in Jiangsu China to explore the effect of CP therapy for mild COVID-19 patients. Patients. From February 2020 to March 2020, a total of 8 subjects were recruited from the were from Jiangsu province. The criteria of the donors were as follows: 1) two consecutively negative results of sputum SARS-CoV-2 by RT-PCR assay for more than 1 week, 2) normality of body temperature for more than 1 week, 3) resolution of respiratory tract symptoms, 4) post onset of illness for more than 3 weeks. Meanwhile, the donors met the blood donor eligibility criteria for plasma donation, including age, weight, reasonable-sized antecubital veins. Plasma preparation procedure and quality control. Convalescence plasma for treatment was collected from 25 donors. A 200-to 400-mL ABO-compatible plasma sample was harvested from each donor and then was divided and stored as 200-mL aliquots at 4 °C. Before being stored, SARS-CoV-2 RNA in the CP was detected by RT-PCR assay. The results of SARS-CoV-2 RNA detections were negative. The serology screening for hepatitis B and C virus, HIV, and syphilis spirochete was negative. Treatments. All patients received antiviral therapy and other supportive care, while some patients received antibiotic treatment, and oxygen support. One dose of 200-to 400-mL of inactivated CP was transfused into the patients within 4 h following the WHO blood transfusion protocol. One patient received total 625-ml CP from three times CP transfusions and other patients received once 200-to 400-ml CP transfusion. Clinical information of all enrolled patients was retrieved from the hospital electronic history system, including the baseline demographic data, days of illness duration, presenting symptoms, different kinds of examinations, and methods of treatment. The SARS-CoV-2 RNA from the serum sample was monitored during treatment. SPSS20.0. and GraphPad Prism 7.0. were applied to conduct data statistics and plot graphs. (seven males and one female) were enrolled and received CP transfusion. The age of eight patients ranged from 44.00y to 80.00y and the median age was 69.50y (interquartile range [IQR], 52.00y to 76.50y). Just one patient was female in the patients. There were 3 patients with no comorbidities, 1 with hypertension and 4 with hypertension and diabetes. The main symptoms were cough (8/8), shortness of breath (4/8), fever (3/8) and fatigue (2/8). The J o u r n a l P r e -p r o o f median SpO2 of the patients without oxygen therapy was 97% (IQR 92% to 99%). The details of clinical characteristics showed in Table 1 . In these patients, 3 patients Combined bacterial infection. In the therapies of the patients, one patient did not receive anti-SARS-CoV2 treatment, the other patients treated with Arbidol hydrochloride, lopinavir ritonavir, hydroxychloroquine sulphate, ribavirin singly or multiply. For details, please refer to Table S1. The median time from onset of symptoms to hospital admission and CP transfusion was 8.00 d (IQR 7.00 d to 11.25 d) and 20.00 d (IQR 11.00 d to 22.75 d), respectively. The baseline examining data in three days before CP transfusion showed in Table 2 . In our study, all patients treated with at least once CP transfusion. The symptoms of all patients improved after CP treatments and the ranges of pulmonary lesions in all patients were reduced within 7 days after CP treatments. As we have already known, convalescent plasma contains antibodies, anti-inflammatory cytokines, albumin, protein C and S, anti-clotting factors and so on. The immune globulin in CP can blockade autoreactive recipient antibodies and then reduce autoinflammatory [8, 9] . An important pathogenesis of COVID-19 is an over-activation of the immune system probably coming with systemic hyper-inflammation or "cytokine storm" [10, 11] . In this sense, CP treatment may reduce over-activation of the immune system and inhibit complement cascade. The results of the study in severe COVID-19 patients showed CP therapy improved the clinical symptoms of 9 in 10 patients [6] . Meanwhile the patients treated with CP in early stages of COVID-19 showed a rapid increase of lymphocyte counts and a decrease of CRP. However, the patients with severe COVID-19, CP therapy added to standard treatment, compared with standard treatment alone, did not result in a statistically significant improvement in time to clinical improvement within 28 days in the randomized clinical trial [12] . In our research, the lymphocyte counts of half J o u r n a l P r e -p r o o f patients increased after CP treatment. In same situation, the levels of LDH, CK and AST tended to decline. More interestingly, the patients with normal CRP levels had transient increased in CRP after CP transfusion, however, the patients with abnormal CRP levels decreased in CRP. So the immunomodulatory effects of CP in COVID-19 patients may be bidirectional. IgG in CP can activate Fcγ receptor [13] . Fcγ receptors are found in about all immune cells. These receptors are critical factors in modulating or inhibiting activity of immune cells, including lymphocytes. Meanwhile, CP transfusion may enhance anti-inflammatory properties of DCs and then reduce antigenic presentation of T cells [14] . So CP therapy can reduce the excessive inflammatory stimuli in patients with COVID-19 [15] . More importantly, CP can provide neutralizing antibodies to promote virus clearance, so CP can enhance antiviral immunity in the COVID-19 patients with insufficient antiviral immunity. Thus, this is probably the reason that the patients with normal CRP have showed a transient increase in CRP. About the effects of CP therapy on virus clearance, the vast majority of the patients in our research got negative SARS-CoV-2 nucleic acids within one week after CP transfusion. Especially, the viral nucleic acids of all patients with a brief increase in CRP became negative in three days after CP transfusion. Thus, CP therapy may be effective for viral removal, particularly in the patients with insufficient antiviral immunity. SARS-CoV infection induces IgG antibodies production against nucleoprotein (N) that can be detected at day 4 after the onset of disease and with seroconversion at day 14 [16] . Neutralizing antibodies are crucial in virus clearance. In SARS-CoV and MERS was discovered that NAbs bind to Spike1-Receptor Binding Protein (S1-RBD), S1-N-terminal domain and S2, thus inhibiting their entry, limiting viral amplification [17] . Thus,the presence of NAbs in the recipients probably restricts viral infection [5] . The plasma obtained from the donors and transfused in the recipients on the same day lead to decreased viral load. CP therapy in our research showed the same effects and seemed to be more effective in the COVID-19 patients with insufficient antiviral immunity. However, the effects of CP on viral clearance may be different for the COVID-19 patients with different immune status. The eldest patient with pulmonary bacterial infection and hypertension in our study had a long period of viral clearance after CP transfusion. After This pilot study shows the potential benefits of CP for treeting mild COVID-19 patients. Meanwhile, CP probably enhances the inflammatory response to SARS-CoV-2 temporarily in the patients with insufficient antiviral immunity. However, the effects of CP are transient. Thus, repeating CP transfusion is required and would be more beneficial. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy Use of convalescent plasma therapy in SARS patients in Hong Kong Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma Effectiveness of convalescent plasma therapy in severe COVID-19 patients Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Pooled normal human polyspecific IgM contains neutralizing anti-idiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease Mechanisms of action of intravenous immunoglobulin Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial Anti-inflammatory actions of intravenous immunoglobulin Indirect inhibition of in vivo and in vitro T-cell responses by intravenous immunoglobulins due to impaired antigen presentation Convalescent plasma in Covid-19: Possible mechanisms of action Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus The spike protein of SARS-CoV--a target for vaccine and therapeutic development We thank all participants for their contributions. This study supported by grants from the